CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
3.490
+0.140 (4.18%)
At close: Jun 26, 2026, 4:00 PM EDT
3.410
-0.080 (-2.29%)
After-hours: Jun 26, 2026, 7:55 PM EDT
CervoMed Employees
CervoMed had 15 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
15
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$139,268
Profits / Employee
-$2,002,433
Market Cap
47.21M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 15 | 0 | - |
| Dec 31, 2024 | 15 | 7 | 87.50% |
| Dec 31, 2023 | 8 | 4 | 100.00% |
| Dec 31, 2022 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 118 |
| Mereo BioPharma Group | 39 |
| PDS Biotechnology | 21 |
| Veru Inc. | 20 |
| Lantern Pharma | 16 |
| Apollomics | 14 |
| Eloxx Pharmaceuticals | 10 |
| Hyperion DeFi | 9 |
CRVO News
- 5 days ago - CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 9 days ago - CervoMed announces $10M registered direct offering priced at-the-market - TheFly
- 9 days ago - CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 10 days ago - CervoMed receives notice of allowance from USPTO on neflamapimod - TheFly
- 10 days ago - CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042 - GlobeNewsWire
- 13 days ago - CervoMed Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference - Transcripts
- 13 days ago - CervoMed Slides: 7th Annual HCW Neuro Perspectives Hybrid Conference - Filings
- 16 days ago - CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit - GlobeNewsWire